Scientists at Ankara University (AU) have developed an artificial intelligence-supported application that could enable the ...

Discover NovoCure's Q1 2025 earnings insights, including Optune Lua's NSCLC progress, global market growth, and strong revenue performance.

Non-small cell lung cancer: current treatment and future advances ... our 10-year forecasts for annual sales growth and operating margin remain. We sell different types of products and services ...

AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a pharmaceutical giant with a market capitalization of $223 billion and an impressive 82% gross profit margin according ... Union for the treatment of adult ...

A few years earlier in 2012, the 90-year-old retired rail engineer, from Crewe in Cheshire, had seen his wife Mary suffer throughout her chemotherapy treatment ... stage 4 lung cancer in 2019.

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

NovoCure (NASDAQ:NVCR), a leader in oncology treatments using Tumor Treating ... arrays for NSCLC—non-small cell lung ...

Experimental Cancer Drug Could Streamline Standard Tuberculosis Treatment and Prevent Post-TB Lung Disease, Study Suggests Apr. 21, 2025 — An experimental drug now in clinical trials as a cancer ...

Q1 2025 Earnings Call Transcript April 24, 2025 NovoCure Limited beats earnings expectations. Reported EPS is $-0.31, ...

Advanced Treatments Create New Prospects for Patients and Their Healthcare Providers New FDA-approved medical treatments can be transformative for patients and families, often providing them with more ...

AstraZeneca’s efforts to move its top oncology drugs into earlier treatment settings have been lifted by positive data for Tagrisso and Imfinzi in lung cancer. AZ and other cancer drug ...

Shares of NovoCure ( NVCR 0.43%) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m. ET after ...